Valar Labs Gets FDA Breakthrough Device Nod for Vesta Bladder Cancer Risk Test

Valar Labs announced that the U.S. FDA granted a Breakthrough Device Designation to Vesta Bladder Risk Stratify Dx. Vesta, Valar’s genitourinary-focused portfolio of AI-powered pathology tests, supports Valar developing diagnostics predicting cancer treatment response from routine pathology slides.

According to Valar Labs, FDA’s designation is the first given to an AI-powered digital pathology prognostic test in bladder cancer. Valar Labs calls it a “significant milestone” both in computational pathology and, more crucially, for patients with bladder cancer.

FDA Gives Valar a Boost

The Breakthrough Device Program expedites development and review of medical devices providing improved effectiveness in diagnosis or treatment. This is particularly applicable to life-threatening or irreversibly debilitating conditions, and largely unmet medical needs.

Regarding bladder cancer, globally one of the most common malignancies, most patients are diagnosed at the non-muscle-invasive stage. Tumors are often treatable, but clinically speaking, behave heterogeneously, resulting in a wide range of patient experiences. Clinical and pathologic features that urologists and oncologists use to estimate risk—grade, stage, tumor size—are valuable but imperfect.

How Vesta Tool Works

Vesta Bladder Risk Stratify Dx works by applying Vesta’s proprietary AI foundation models to hematoxylin and eosin-stained pathology slides. These slides are produced as a routine, standard part of clinical care. What the Vesta platform does, however, is prognosticate and then generate a risk assessment for patients.

Valar Labs Chief Medical Officer Trevor Royce, MD, said this approach addresses a problem that clinicians have battled for decades.

“Urologists have managed bladder cancer with prognostic tools that leave too many patients in the gray zone,” Royce said. “Vesta Bladder Risk Stratify Dx gives clinicians the resolution they need to match treatment intensity to each patient’s true biological risk.”

“Vesta Bladder has been a breakthrough in biomarker-driven oncology,” Valar Labs Co-Founder and CEO Anirudh Joshi said. “[It serves] a population of patients that previously had limited access to precision medicine.”

With Breakthrough Device status, Vesta Bladder Risk Stratify Dx now benefits from potentially expedited FDA clearance, and eventually patient access.